Balance Sheet StrengthA high equity ratio (66.7%) indicates durable financial stability and low reliance on external financing. This conservatism supports investment capacity and resilience during industry cycles, allowing the company to fund operations or opportunistic spending without immediate refinancing risk.

Operational ScaleA workforce of ~1,485 suggests meaningful operational and manufacturing capacity in specialty/generic drugs. Sustained headcount supports production continuity, regulatory compliance and incremental R&D capability, which underpins long-term product supply and execution of strategic initiatives.

Improving Net Profit MarginA modest improvement in net margin indicates the company has captured some operational efficiencies despite revenue pressures. Sustaining and expanding these efficiencies can preserve cash generation and provide room to reinvest in product development or margin-restoring initiatives over the medium term.

Bears Say

Declining RevenueNear 6% revenue contraction reflects erosion of sales momentum which, if persistent, undermines scale economics, weakens bargaining power with suppliers, and reduces available funds for R&D and commercialization, making long-term competitive positioning harder to sustain.

Gross Margin CompressionA ~10 percentage-point drop in gross margin signals material cost pressures or pricing erosion. This reduces operating leverage and the firm's ability to fund SG&A or R&D internally, increasing dependency on efficiency gains or structural fixes to restore sustainable profitability.

Cash Flow WeaknessZero operating and free cash flow is a persistent structural concern: it limits ability to fund capex, R&D, or dividends from operations and heightens reliance on external financing. This constraint weakens strategic flexibility and raises risk during industry or funding stresses.

8329 FAQ

What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.13 and its highest was HK$0.38 in the past 12 months.

What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$266.80M.

When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 38 days.

How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H released its earnings results on Aug 22, 2025. The company reported HK$0.012 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.012.

Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?

According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.164 which represents an annual dividend yield of 3.51%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here

What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.

What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H reported an EPS of HK$0.012 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.75%.

Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8329

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

0.72%

Trailing 12-Months

Asset Growth

-20.46%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H

Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products. In addition, the company manufactures herbal medicines and generic drugs products, as well as medical devices. The company is based in Shenzhen, the People's Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.